2024
Self-Reported Methamphetamine Use Versus Biological Testing Among Treatment-Seeking Patients
Gholami J, Ardeshir M, Rostam-Abadi Y, Baheshmat S, Shadloo B, Rahimi-Movaghar A. Self-Reported Methamphetamine Use Versus Biological Testing Among Treatment-Seeking Patients. Iranian Journal Of Psychiatry And Behavioral Sciences 2024, 18 DOI: 10.5812/ijpbs-148330.Peer-Reviewed Original ResearchNegative predictive valuePositive percent agreementMethamphetamine use disorderMethamphetamine useTreatment-seeking patientsSelf-reported useCohen's kappa statisticUrine testsUse disorderPercent agreementKappa statisticNo significant factorsCross-sectional studyDrug treatment centersMonitoring treatmentPredictive valueMethamphetaminePatientsImmunoassay techniqueTreatment-seekingTreatment centersUrinalysisUrineAddiction studiesTreatmentReducing Care Overuse in Older Patients Using Professional Norms and Accountability : A Cluster Randomized Controlled Trial.
Persell S, Petito L, Lee J, Meeker D, Doctor J, Goldstein N, Fox C, Rowe T, Linder J, Chmiel R, Peprah Y, Brown T. Reducing Care Overuse in Older Patients Using Professional Norms and Accountability : A Cluster Randomized Controlled Trial. Annals Of Internal Medicine 2024, 177: 324-334. PMID: 38315997, PMCID: PMC12080469, DOI: 10.7326/m23-2183.Peer-Reviewed Original ResearchCase-based educationHealth systemOlder primary care patientsCluster Randomized Controlled TrialPrimary care internal medicineClinical decision support toolRates of uncontrolled diabetesClinician decision supportPrimary care patientsPrimary care cliniciansProstate-specific antigenOvertreatment of diabetesNational Institute on AgingMonths of interventionDecision supportRates of PSA testingHemoglobin A<sub>1c</sub>Older adult patientsInstitute on AgingSingle health systemUrine testsPSA testingRandomized Controlled TrialsCare cliniciansEmergency care
2023
Analysis of Drugs in Saliva of US Military Veterans Treated for Substance Use Disorders Using Supported Liquid Extraction and Surface-Enhanced Raman Spectral Analysis
Farquharson S, Shende C, Newcomb J, Petrakis I, Arias A. Analysis of Drugs in Saliva of US Military Veterans Treated for Substance Use Disorders Using Supported Liquid Extraction and Surface-Enhanced Raman Spectral Analysis. Molecules 2023, 28: 2010. PMID: 36903255, PMCID: PMC10004423, DOI: 10.3390/molecules28052010.Peer-Reviewed Original ResearchConceptsOpioid use disorderSubstance-related disordersUS military veteransUse disordersMilitary veteransDrug useIllicit drugsSubstance use disordersDrug overdose deathsIllicit drug useML of salivaBuprenorphine adherenceTreatment medicationsUrine testsOverdose deathsPatients' salivaDisease controlPatient samplesBuprenorphinePOC analyzerDrugsVulnerable populationsCare analyzerMedicationsDisorders
2022
Compliance or Abuse? Detectable hydromorphone in patients taking oxycodone
Villalba C, Choucair I, El-Khoury J. Compliance or Abuse? Detectable hydromorphone in patients taking oxycodone. American Journal Of Clinical Pathology 2022, 158: s5-s6. DOI: 10.1093/ajcp/aqac126.008.Peer-Reviewed Original ResearchBilateral upper extremity paresthesiasMetabolites of oxycodoneUpper extremity paresthesiasUrine drug monitoringUrine samplesMiddle-aged womenQuality improvement projectPositive urine samplesAspen collarOpioid therapyOxycodone preparationsMechanical fallOpioid medicationsExtremity paresthesiasCervical diskectomyChronic painSurgical interventionUrine testsOrthopaedic servicesSpinal fusionOxycodonePatientsHydromorphoneDrug monitoringHydrocodoneUrine testing to differentiate glomerular from tubulointerstitial diseases on kidney biopsy
Tran AC, Melchinger H, Weinstein J, Shaw M, Kent C, Perazella MA, Wilson FP, Parikh CR, Moledina DG. Urine testing to differentiate glomerular from tubulointerstitial diseases on kidney biopsy. Practical Laboratory Medicine 2022, 30: e00271. PMID: 35465621, PMCID: PMC9018443, DOI: 10.1016/j.plabm.2022.e00271.Peer-Reviewed Original ResearchTubulointerstitial diseaseKidney biopsyGlomerular diseaseUrine albuminHistological diagnosisUrine uromodulinUrine testsHigher urine albuminUrine sediment microscopyCohort of participantsDipstick hematuriaTubular injuryAppropriate patientsUrine testingMultivariable modelHigher oddsBiopsyClinical decisionSediment microscopyDiseasePatientsHealth biomarkersUrine samplesDiagnosisCohort
2021
Comparison of self-reported substance use with biological testing among treatment-seeking patients with opioid use disorder
Shadloo B, Baheshmat S, Rostam-Abadi Y, Shakeri A, Gholami J, Rahimi-Movaghar A. Comparison of self-reported substance use with biological testing among treatment-seeking patients with opioid use disorder. Journal Of Substance Use And Addiction Treatment 2021, 134: 108555. PMID: 34210569, DOI: 10.1016/j.jsat.2021.108555.Peer-Reviewed Original ResearchConceptsOpioid use disorderSelf-reported opioid useOpioid usePositive percent agreementUrine testsTreatment-seeking patientsCohen's kappa statisticPercent agreementUse disorderKappa statisticNegative predictive valueLonger treatment durationMonitoring treatment adherenceRandom urine testingResults of urinalysisValidity of self-reported drug useCross-sectional studySelf-reported substance useSelf-reported drug useTreatment durationOpioidPredictive valuePatientsTreatment adherenceDrug useBehavioral counseling and abstinence‐contingent take‐home buprenorphine in general practitioners’ offices in Malaysia: a randomized, open‐label clinical trial
Schottenfeld RS, Chawarski M, Mazlan M. Behavioral counseling and abstinence‐contingent take‐home buprenorphine in general practitioners’ offices in Malaysia: a randomized, open‐label clinical trial. Addiction 2021, 116: 2135-2149. PMID: 33404150, DOI: 10.1111/add.15399.Peer-Reviewed Original ResearchConceptsOpioid-negative urine testsBuprenorphine-naloxone treatmentBehavioral counselingPhysician managementBehavioral interventionsUrine testsClinical trialsOpen-label clinical trialTake-home dosesOpioid-dependent patientsWeeks of treatmentOpioid use disorderPrimary care physiciansOpioid-dependent individualsHIV risk behaviorsGeneral practitioner's officeBuprenorphine-naloxoneOpioid usePrimary outcomeCare physiciansTreatment outcomesStudy interventionTreatment accessTreatment groupsUse disorders
2020
Use of Amphetamine-Type Stimulants Among Emergency Department Patients With Untreated Opioid Use Disorder
Chawarski MC, Hawk K, Edelman EJ, O'Connor P, Owens P, Martel S, Coupet E, Whiteside L, Tsui JI, Rothman R, Cowan E, Richardson L, Lyons MS, Fiellin DA, D'Onofrio G. Use of Amphetamine-Type Stimulants Among Emergency Department Patients With Untreated Opioid Use Disorder. Annals Of Emergency Medicine 2020, 76: 782-787. PMID: 32782084, PMCID: PMC8048036, DOI: 10.1016/j.annemergmed.2020.06.046.Peer-Reviewed Original ResearchConceptsUntreated opioid use disorderOpioid use disorderAmphetamine-type stimulant useUse disordersStimulant useAmphetamine-type stimulantsStudy admissionEmergency departmentEmergency department patientsImplementation science studyUrine test resultsFalse discovery rate correctionSubstance use problemsHepatitis CED visitsDepartment patientsReferral protocolsED patientsUrine testsDrug injectionOverdose riskPatientsHealth factorsUnstable housingConcurrent use
2018
Atomoxetine for amphetamine-type stimulant dependence during buprenorphine treatment: A randomized controlled trial
Schottenfeld RS, Chawarski MC, Sofuoglu M, Chooi WT, Zaharim NM, M Yasin MA, Ahmad I, Syed Jaapar SZ, Vicknasingam BK. Atomoxetine for amphetamine-type stimulant dependence during buprenorphine treatment: A randomized controlled trial. Drug And Alcohol Dependence 2018, 186: 130-137. PMID: 29573648, PMCID: PMC5911201, DOI: 10.1016/j.drugalcdep.2018.01.017.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic Uptake InhibitorsAdultAmphetamine-Related DisordersAtomoxetine HydrochlorideBehavior TherapyBuprenorphineBuprenorphine, Naloxone Drug CombinationDepressionDouble-Blind MethodHumansMaleMiddle AgedNarcotic AntagonistsOpioid-Related DisordersPilot ProjectsTreatment OutcomeYoung AdultConceptsATS use disorderPlacebo-treated participantsUse disordersAdverse eventsUrine testsPotential efficacyAmphetamine-type stimulant dependenceAmphetamine-type stimulant useSerious adverse eventsBuprenorphine/naloxoneBetween-group differencesATS dependenceClinical tolerabilityMedication discontinuationBuprenorphine treatmentPrimary outcomeOpioid dependenceClinical trialsITT sampleTreat sampleBehavioral counselingDepressive symptomsDays abstinentAtomoxetineStimulant dependence
2016
Medical treatments for opioid use disorder in Iran: a randomized, double‐blind placebo‐controlled comparison of buprenorphine/naloxone and naltrexone maintenance treatment
Mokri A, Chawarski MC, Taherinakhost H, Schottenfeld RS. Medical treatments for opioid use disorder in Iran: a randomized, double‐blind placebo‐controlled comparison of buprenorphine/naloxone and naltrexone maintenance treatment. Addiction 2016, 111: 874-882. PMID: 26639678, DOI: 10.1111/add.13259.Peer-Reviewed Original ResearchConceptsOpioid-negative urine testsBuprenorphine/naloxoneOpioid use disorderSublingual buprenorphine/naloxoneUrine testsUse disordersOral naltrexoneOpioid abstinenceClinical trialsTreatment retentionDouble-blind placebo-controlled comparisonMean numberDouble-blind clinical trialOpioid use disorder treatmentNaltrexone maintenance treatmentTwo-group parallelEffective opioid use disorder treatmentPlacebo-controlled comparisonUrine toxicology testsPilot clinical trialGroup drug counselingUse disorder treatmentClinical research programBNx groupNTX group
2015
Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system
Springer SA, Brown SE, Di Paola A, Altice FL. Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system. Drug And Alcohol Dependence 2015, 157: 158-165. PMID: 26560326, PMCID: PMC4675147, DOI: 10.1016/j.drugalcdep.2015.10.023.Peer-Reviewed Original ResearchConceptsAlcohol use disorderExtended-release naltrexoneOpioid use disorderXR-NTXUse disordersHIV diseaseFirst injectionDouble-blind placebo-controlled randomized trialSecond injectionPlacebo-controlled randomized trialSubstance use disordersMultivariate regression analysisTreatment of alcoholCorrelates of retentionAntiretroviral therapyStudy drugHIV infectionRandomized trialsUrine testsUrine screensEligible personsDays of releaseHazardous drinkingCocaine useDemographic featuresEvaluation of an implementation of methadone maintenance treatment in China
Marienfeld C, Liu P, Wang X, Schottenfeld R, Zhou W, Chawarski MC. Evaluation of an implementation of methadone maintenance treatment in China. Drug And Alcohol Dependence 2015, 157: 60-67. PMID: 26601934, PMCID: PMC4663107, DOI: 10.1016/j.drugalcdep.2015.10.001.Peer-Reviewed Original ResearchConceptsInjection drug useMethadone maintenance treatmentMMT exposureDrug useMaintenance treatmentUrine testsPositive testOpiate positive urine testsDaily methadone dosesPositive urine testHigher adherence ratesOpioid use disorderNegative urine testsSelf-reported drug useElectronic medical recordsPriority improvement areasMonth drug useMethadone dosesMethadone dosingDose adjustmentAdherence ratesDaily dosesMedical recordsTreatment daysUse disordersBuprenorphine/naloxone treatment practices in Malaysia: Results of national surveys of physicians and patients
Vicknasingam B, Dazali MN, Singh D, Schottenfeld RS, Chawarski MC. Buprenorphine/naloxone treatment practices in Malaysia: Results of national surveys of physicians and patients. Drug And Alcohol Dependence 2015, 152: 164-169. PMID: 25935736, DOI: 10.1016/j.drugalcdep.2015.04.007.Peer-Reviewed Original ResearchConceptsBUP/NXNX treatmentGeneral practitionersPast monthOpiate positive urine testsOptimal treatment effectivenessRoutine toxicology testingToxicology testingBuprenorphine/naloxonePositive urine testUrine toxicology testingIllicit opiate useInjection of heroinInjection of drugsCross-sectional surveyMaintenance treatmentPatient surveyUrine testingUrine testsTreatment responseOpiate usePatient experiencePatientsDispensing practicesDrug useHepatitis C seroconversion in methadone maintenance treatment programs in Wuhan, China
Zhou W, Wang X, Zhou S, Xie N, Liu P, Luo L, Peng J, Liu M, Desrosiers A, Schottenfeld R, Chawarski MC. Hepatitis C seroconversion in methadone maintenance treatment programs in Wuhan, China. Addiction 2015, 110: 796-802. PMID: 25529103, PMCID: PMC4598328, DOI: 10.1111/add.12836.Peer-Reviewed Original ResearchConceptsMethadone maintenance treatmentInjection drug useHCV seroconversionPatients HCVSeroconversion ratesDrug useOpiate positive urine testsHepatitis C virus infectionRisk behaviorsMethadone maintenance treatment patientsMethadone maintenance treatment programHepatitis C seroconversionC virus infectionUrine toxicology resultsHepatitis C virusMaintenance treatment programPotential risk factorsOpiate-dependent individualsCross-sectional surveyHCV seroprevalenceMMT clinicsMaintenance treatmentTreatment patientsC virusUrine tests
2014
Progesterone for the reduction of cocaine use in post-partum women with a cocaine use disorder: a randomised, double-blind, placebo-controlled, pilot study
Yonkers KA, Forray A, Nich C, Carroll KM, Hine C, Merry BC, Shaw H, Shaw J, Sofuoglu M. Progesterone for the reduction of cocaine use in post-partum women with a cocaine use disorder: a randomised, double-blind, placebo-controlled, pilot study. The Lancet Psychiatry 2014, 1: 360-367. PMID: 25328863, PMCID: PMC4199242, DOI: 10.1016/s2215-0366(14)70333-5.Peer-Reviewed Original ResearchCocaine use disorderCocaine usePostpartum womenPost trialUse disordersPlacebo-controlled pilot trialOral micronized progesteronePositive urine testPost-partum womenGroup differencesSelf-reported daysMultiple brain functionsUse of cocaineMicronized progesteroneObstetrical clinicTherapeutic breakProgesterone replacementAdverse eventsUS National InstitutesProgesterone treatmentUrine testsPilot trialRate of submissionStudy biostatisticianProgesterone
2013
Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment
Schottenfeld RS, Chawarski MC, Cubells JF, George TP, Lappalainen J, Kosten TR. Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment. Drug And Alcohol Dependence 2013, 136: 36-42. PMID: 24462581, DOI: 10.1016/j.drugalcdep.2013.12.007.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAlcohol DeterrentsAlcoholismAllelesBuprenorphineCocaine-Related DisordersData Interpretation, StatisticalDisulfiramDNADouble-Blind MethodDrug Therapy, CombinationFemaleGenotypeHumansMaleMiddle AgedNarcotic AntagonistsOpioid-Related DisordersPharmacogeneticsPolymerase Chain ReactionSample SizeTreatment OutcomeYoung AdultConceptsUrine testsCocaine useMechanism of actionCocaine dependenceClinical trialsWeeks abstinencePlacebo-controlled clinical trialEfficacy of disulfiramPharmacogenetics of responseDouble-blind treatmentBuprenorphine maintenance treatmentRandomized clinical trialsOpioid-dependent participantsT allele carriersFrequent cocaine useDopamine β-hydroxylaseBuprenorphine treatmentPrimary outcomeTreat comparisonMaintenance treatmentPharmacogenetic interactionsTreatment responseTT genotypeCocaine abstinenceConsecutive weeks
2011
Contingency management with community reinforcement approach or twelve-step facilitation drug counseling for cocaine dependent pregnant women or women with young children
Schottenfeld RS, Moore B, Pantalon MV. Contingency management with community reinforcement approach or twelve-step facilitation drug counseling for cocaine dependent pregnant women or women with young children. Drug And Alcohol Dependence 2011, 118: 48-55. PMID: 21454024, DOI: 10.1016/j.drugalcdep.2011.02.019.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlcoholismAmbulatory CareBehavior TherapyCentral Nervous System StimulantsCocaineCocaine-Related DisordersComorbidityDepressive Disorder, MajorFemaleHumansMaleMaternal BehaviorPregnancyPregnancy ComplicationsPregnant PeoplePsychiatric Status Rating ScalesReinforcement, PsychologyResidence CharacteristicsRewardSelf-Help GroupsTime FactorsTreatment OutcomeUrban PopulationConceptsTwelve-step facilitationCommunity Reinforcement ApproachCocaine-dependent pregnant womenDependent pregnant womenPregnant womenUrine testsContingency managementCocaine abstinenceEfficacy of CMYoung childrenSignificant public health problemPrimary outcome measureCocaine-dependent womenChild-bearing yearsPublic health problemSecondary outcomesHigher proportionOutcome measuresDrug counselingReinforcement approachCocaine abuseHealth problemsGreater efficacyMonetary vouchersDifferential efficacy
2009
Pediatric Urolithiasis: Medical Treatment and Outcomes
Wong J, Weiss R, Friedman S, Pagala M, Franco I. Pediatric Urolithiasis: Medical Treatment and Outcomes. Journal Of Pediatric Urology 2009, 5: s34. DOI: 10.1016/j.jpurol.2009.02.039.Peer-Reviewed Original ResearchPotassium citrateFull metabolic evaluationPotassium citrate groupsMainstay of treatmentResultsThe mean ageUntreated controlsMethodsBetween 2002Standard therapyRetrospective studyMean ageCombination therapyMetabolic evaluationUrine testsUrolithiasis patientsPatientsExcretion rateThiazidesTherapySignificant riskCitrate groupUric acidT-testCalcium oxalateSignificant improvementHypocitraturia
2007
Behavioral drug and HIV risk reduction counseling (BDRC) with abstinence-contingent take-home buprenorphine: A pilot randomized clinical trial
Chawarski MC, Mazlan M, Schottenfeld RS. Behavioral drug and HIV risk reduction counseling (BDRC) with abstinence-contingent take-home buprenorphine: A pilot randomized clinical trial. Drug And Alcohol Dependence 2007, 94: 281-284. PMID: 18164145, DOI: 10.1016/j.drugalcdep.2007.11.008.Peer-Reviewed Original ResearchConceptsBuprenorphine maintenance treatmentOpioid-negative urine testsHIV risk reduction counselingRisk reduction counselingHIV risk behaviorsBehavioral drugReduction counselingUrine testsClinical trialsDrug counselingRisk behaviorsSelf-reported HIV risk behaviorsTake-home dosesUrine toxicology testsHeroin-dependent individualsIndividual drug counselingSelf-reported drug useMaintenance treatmentMedication adherenceLimited counselingBuprenorphineDrug useConsecutive abstinenceToxicology testsOverall proportion
2006
Incidence and Predictors of Serious Bacterial Infections Among 57- to 180-Day-Old Infants
Hsiao AL, Chen L, Baker MD. Incidence and Predictors of Serious Bacterial Infections Among 57- to 180-Day-Old Infants. 2006, 117: 1695-1701. PMID: 16651326, DOI: 10.1542/peds.2005-1673.Peer-Reviewed Original ResearchConceptsSerious bacterial illnessWhite blood cell countDirect fluorescent antibodyBlood cell countPositive direct fluorescent antibodyCell countOlder infantsEtiology of feverHeight of feverOlder febrile infantsSerious bacterial infectionsRespiratory syncytial virusMonths of ageFebrile infantsPneumococcal diseaseBacterial meningitisVaccine eraRespiratory virusesProspective studySyncytial virusLumbar punctureUrine testsBacterial illnessNasal swabsFever
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply